<DOC>
	<DOCNO>NCT01949441</DOCNO>
	<brief_summary>House Dust Mites ( HDMs ) arachnids infest bedding , carpet , upholstered furniture fabric . Like many allergen , exposure HDMA sensitise patient associate poor lung function , great medication requirement asthma symptom well chronic rhinosinusitis symptom . In contrast allergen , evidence HDMA lead development asthma , addition exacerbate pre-existing asthma HDM-sensitised patient . ToleroMune House Dust Mite ( TM-HDM ) , combination seven Synthetic Peptide Immuno-Regulatory Epitopes , develop treatment HDM allergy . This study assess tolerability ToleroMune House Dust Mite subject control asthma house dust mite-induced rhinoconjunctivitis .</brief_summary>
	<brief_title>ToleroMune House Dust Mite ( HDM ) Tolerability Study</brief_title>
	<detailed_description>A multi-centre , randomised , double-blind , placebo-controlled , parallel-group , multiple dose study evaluate tolerability four intradermal dos TM-HDM subject control asthma HDM-induced rhinoconjunctivitis .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Male female , age 1865 year . Asthma control Step 1 Step 2 treatment define GINA four week prior randomisation . Asthma control Step 1 Step 2 treatment define GINA four week prior randomisation . No change asthma controller treatment ( dose , frequency ) four week prior randomisation . A reliable history consistent rhinoconjunctivitis exposure HDM least 1 year require symptomatic treatment least one occasion year prior randomisation Positive skin prick test Dermatophagoides pteronyssinus average wheal diameter least 5 mm large produce negative control . ImmunoCAP® Dermatophagoides pteronyssinusspecific Immunoglobulin E ≥ 0.35 kU/L . History lifethreatening asthma Asthma exacerbation 12 week prior randomisation Prebronchodilator Forced Expiratory Volume 1 Second ( FEV1 ) &lt; 80 % predict , regardless cause . Postbronchodilator FEV1/Forced Vital Capacity ratio &lt; 0.7 . Concurrent respiratory disease would confound study participation affect subject safety . NonHDM allergy may significantly interfere result study . 7 . Previous immunotherapy treatment HDM allergen 1 month within 5 year prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HDM Allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>ToleroMune HDM</keyword>
</DOC>